Europe Clears RejuvenAir, a New Therapy for COPD with Chronic Bronchitis

Chronic bronchitis can be a difficult disease to live with, but when it’s coupled with COPD it can be truly debilitating. There are medications available that help to reduce mucus production and coughing, but these don’t really help the condition itself.

CSA Medical, a Boston-based company, just won European regulatory approval to introduce the first therapeutic option that lessens symptoms of chronic bronchitis in COPD patients while helping the lungs to regenerate healthy cells to replace diseased ones.

The RejuvenAir system delivers liquid nitrogen at -320◦F (-196◦C) to specific areas of the lungs that are damaged from chronic bronchitis, freezing the epithelial surface layer of the airways and killing the cells within. In the process, the extracellular matrix remains unharmed and new cells are free to grow into the treated space, hopefully producing long lasting improvements in patient lung function.

“RejuvenAir Metered Cryospray can be safely delivered in patients with COPD and demonstrates clinical meaningful improvements in quality of life and patient-reported outcome scores out to 12 months,” said Professor Pallav Shah, M.D., F.R.C.P. from the Royal Brompton, London. “This is a promising new therapy for the millions of people who suffer from chronic bronchitis.”

Flashback: RejuvenAir Cryospray for Treating COPD with Chronic Bronchitis Going on Trial